Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry

Atherosclerosis. 2018 Oct:277:419-424. doi: 10.1016/j.atherosclerosis.2018.05.040.

Abstract

Background and aims: Familial hypercholesterolemia (FH) is under-diagnosed and under-treated in most of the world, including Canada. National registries play a key role in identifying patients with FH, understanding gaps in care, and advancing the science of FH to better treat these patients.

Methods: FH Canada has established a national registry across 19 academic sites acting as "hubs" in Canada to increase awareness and access to standard-of-care therapies.

Results: To-date, more than 3000 patients with FH have been entered into a secure, web-based database. Early outcomes of this initiative include a greater understanding of treatment gaps for patients with FH in Canada, the development of a new, simplified Canadian definition of FH, and tools to aid in the diagnosis of FH, including imputation of baseline levels of LDL cholesterol.

Conclusions: As the national registry expands in size and scope, further learning will emerge with ultimate benefit for the diagnosis and treatment of FH in Canada.

Keywords: Atherosclerosis; Familial hypercholesterolemia; LDL; Lipids; PCSK9; Statins.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticholesteremic Agents / therapeutic use*
  • Biomarkers / blood
  • Canada
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control
  • Cholesterol, LDL / blood*
  • Databases, Factual
  • Down-Regulation
  • Drug Therapy, Combination
  • Female
  • Genetic Predisposition to Disease
  • Heredity
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / epidemiology
  • Hyperlipoproteinemia Type II / genetics
  • Male
  • Middle Aged
  • PCSK9 Inhibitors
  • Pedigree
  • Phenotype
  • Prevalence
  • Proprotein Convertase 9 / metabolism
  • Registries
  • Risk Assessment
  • Risk Factors
  • Serine Proteinase Inhibitors / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • Serine Proteinase Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9

Grants and funding